

For immediate release

Press release Forbion



Forbion invests in Autonomic Technologies Europe GmbH

Third investment by newly raised Forbion Capital Fund III

Naarden, Netherlands, May 12th, 2015 – Forbion Capital Partners (Forbion) today announced their investment in Autonomic Technologies Europe GmbH (ATI GmbH) as part of the USD 38 M transatlantic series D round raised by Autonomic Technologies Inc. (ATI Inc), developer and manufacturer of Pulsante™, a microstimulator to treat severe headaches.

Forbion invested alongside investor Edmond de Rothschild Investment Partners, Paris, and the syndicate was completed by existing investors Kleiner Perkins Caufield and Byers, InterWest Partners, Novartis Venture Fund, Aberdare Ventures, Versant Ventures and the Cleveland Clinic. Martien van Osch, Managing Partner at Forbion Capital Partners, will join ATI's Board of Directors on behalf of Forbion.

ATI has started commercialization of the Pulsante microstimulator in Europe and established Autonomic Technologies Europe GmbH, a wholly owned subsidiary in Germany, to further expand European commercialization. In addition, the company will use proceeds from the financing to fund the ongoing IDE study in the USA.

"The investments from our new European investors together with the support from our existing investors provide recognition of ATI's strong clinical data and our unique Pulsante microstimulator for severe headache," said Ben Pless, President and Chief Executive Officer of Autonomic Technologies. "We are now well financed to further build out our leadership position in the growing field of neurostimulation in headache, expanding our launch to other countries in Europe and expanding the clinical evidence base of our minimally invasive treatment into other indications."

"The investment in ATI perfectly fits our new FCF III fund's strategy," commented Martien van Osch. "The Pulsante microstimulator addresses a high unmet medical need for patients suffering from severe, disabling headaches. It is a minimally invasive device with strong safety and efficacy data from a European randomized clinical trial and the only system approved for use in patients suffering from so-called cluster headaches. Our investment will allow the company to expand its commercial operations in Europe whilst additional clinical studies are performed in the US and Europe to expand markets and indications."

"The combination of a strong management team, with deep experience in bringing new neurostimulation devices to patients and markets, and a top investor syndicate, creates a strong foundation for future success", added Holger Reithinger, General Partner at Forbion and on the ATI deal team. "Treating cluster headaches effectively will not only be a tremendous relief for the patients and their families, but it will also have a big impact on the socioeconomic burden by

reducing healthcare service costs and indirect costs of lost work days and decreased work efficacy.”

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

--Ends--

For further information please contact

Martien van Osch

Forbion Capital Partners

+31 35 699 3019

Martien.van.osch@forbion.com

Instinctif Partners (on behalf of Forbion)

Melanie Toyne Sewell / Robert Mayer

+44 20 7457 2020 / +49 89 3090 5189 13

forbion@instinctif.com

About Forbion Capital Partners

Forbion Capital Partners is a dedicated Life Sciences venture capital firm with offices in Naarden, The Netherlands, Munich, Germany and representation in Boston, US. Forbion invests in life sciences companies in drug discovery & development as well as medical device companies addressing substantial unmet medical needs. Forbion's investment team of ten investment professionals has built an impressive performance track record since the late nineties with successful investments in Rhein Biotech, Crucell, Neutec, Glycart, Borealis, Impella, Alantus, Acorda (ACOR), Fovea, Insmed (INSM), PanGenetics, Argenta Discovery, BioVex, Pathway Medical, CircuLite, bluebird bio (BLUE), uniQure (QURE), Argos (ARGS), arGEN-X (ARGX.BR), Santaris and PneumRx. Forbion also operates a joint venture with BioGeneration Ventures, who manages two separate seed and early stage funds focused on Benelux. Including the new fund FCF III, Forbion manages EUR 540M across 5 funds. Its investors include the EIF through its European Recovery Programme (ERP), LfA and Dutch Venture Initiative (DVI) facilities.

About Autonomic Technologies

Autonomic Technologies, Inc. (ATITM) is a medical device company headquartered in the San Francisco Bay Area with offices in Germany and Switzerland, focused on the development and commercialization of innovative therapies for the treatment of autonomic disorders, particularly severe headache. The company's initial product, the Pulsante microstimulator, is CE marked in Europe for the treatment of cluster headache. The device is also under an IDE study in the US for the treatment of chronic cluster headache. For more information, please visit: www.pulsante.eu or www.ati-spg.com.

Thomas Bianchi
Senior Director of Marketing
+1 6502166107
tbianchi@ati-spg.com